<SEC-DOCUMENT>0001193125-21-177693.txt : 20210601
<SEC-HEADER>0001193125-21-177693.hdr.sgml : 20210601
<ACCEPTANCE-DATETIME>20210601060834
ACCESSION NUMBER:		0001193125-21-177693
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210601
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210601
DATE AS OF CHANGE:		20210601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		21982738

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d19128d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20210601" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt/2020-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2021-06-01_to_2021-06-01" name="dei:EntityCentralIndexKey" contextRef="duration_2021-06-01_to_2021-06-01">0000318154</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2021-06-01_to_2021-06-01" name="dei:AmendmentFlag" contextRef="duration_2021-06-01_to_2021-06-01">false</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20210601.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-06-01_to_2021-06-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-01</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-01</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-01</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-06-01_to_2021-06-01">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-06-01_to_2021-06-01" format="ixt:datemonthdayyearen">June 1, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:EntityRegistrantName">Amgen Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:EntityFileNumber">001-37702</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:EntityTaxIdentificationNumber">95-3540776</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr> </table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-06-01_to_2021-06-01">One Amgen Center Drive</ix:nonNumeric><br /><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-06-01_to_2021-06-01">Thousand Oaks</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-06-01_to_2021-06-01" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom"> </td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-06-01_to_2021-06-01">91320-1799</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:CityAreaCode">805</ix:nonNumeric>) <ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:LocalPhoneNumber">447-1000</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-06-01_to_2021-06-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-06-01_to_2021-06-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-06-01_to_2021-06-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr> </table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Securities Registered under Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:Security12bTitle">Common Stock $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:TradingSymbol">AMGN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member" name="dei:Security12bTitle">1.250% Senior Notes Due 2022</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member" name="dei:TradingSymbol">AMGN22</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" name="dei:Security12bTitle">2.000% Senior Notes Due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" name="dei:TradingSymbol">AMGN26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr> </table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company <ix:nonNumeric contextRef="duration_2021-06-01_to_2021-06-01" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div> <p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry Into a Material Definitive Agreement.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;1, 2021 (the &#8220;<span style="text-decoration:underline">Effective Date</span>&#8221;), Amgen Inc. (&#8220;<span style="text-decoration:underline">Amgen</span>&#8221;) entered into a License and Collaboration Agreement (the &#8220;<span style="text-decoration:underline">Collaboration Agreement</span>&#8221;) with Kyowa Kirin Co., Ltd. (&#8220;<span style="text-decoration:underline">KKC</span>&#8221;), pursuant to which Amgen and KKC will collaborate on the development and commercialization of KHK4083 (the &#8220;<span style="text-decoration:underline">Product</span>&#8221;), an anti-OX40 fully human monoclonal antibody, worldwide, except Japan (the &#8220;<span style="text-decoration:underline">Territory</span>&#8221;).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement and transactions contemplated thereunder have been approved by the boards of directors of both Amgen and KKC. The consummation of the Agreement is subject to obtaining any necessary consents and approvals, including those that may be required by regulators.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Collaboration Agreement, Amgen will lead the development, manufacturing and commercialization for the Product in the Territory, under the oversight of joint governing bodies. Additionally, KKC will <span style="white-space:nowrap">co-promote</span> the Product with Amgen in the U.S. and <span style="white-space:nowrap">co-market</span> the Product in South Korea, and KKC will also have <span style="white-space:nowrap">opt-in</span> rights to <span style="white-space:nowrap">co-promote</span> the Product in certain other markets outside the U.S. Amgen and KKC will share global development costs and U.S. commercialization costs. Amgen will book all revenue from sales in the Territory. KKC will provide to Amgen certain drug supplies necessary for the development of the Product, with the understanding that Amgen will assume responsibility for manufacturing commercial product.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amgen will make a $400&#160;million <span style="white-space:nowrap">one-time</span> upfront payment, as well as future contingent milestone payments potentially worth up to an additional $850&#160;million, and pay significant royalties on any net sales in the U.S. and significant, tiered royalties on any net sales in the <span style="white-space:nowrap">Ex-U.S</span> Territory, until the latest of (i)&#160;the expiration of the last valid patent claim owned or exclusively controlled by KKC, (ii)&#160;the expiration of regulatory exclusivity, or (iii)&#160;the earlier of (x)&#160;ten years after the first commercial sale of such product in the country of sale or (y) 20 years after the first commercial sale of such product anywhere in the world.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement contains customary representations, warranties and covenants by the parties, and will continue in effect unless terminated by either party pursuant to its terms. Either Amgen or KKC may terminate the Collaboration Agreement in its entirety for the other side&#8217;s insolvency, uncured material breach or failure to comply with specified compliance provisions. Amgen may terminate the Collaboration Agreement for convenience upon prior written notice.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the term of the Collaboration Agreement, Amgen and KKC are subject to certain restrictions in the Territory and worldwide related to the clinical development, commercial manufacture, distribution and commercialization of certain products that, as a therapeutic mechanism of action, are directed to the same target as the Product and are expected to treat the same inflammation-related diseases and conditions as treated by the Product.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the terms of the Collaboration Agreement is not complete and is qualified in its entirety by reference to the Collaboration Agreement, a copy of which Amgen intends to file as an exhibit to a subsequent periodic report.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amgen has issued a press release which is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.</p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-1-</p></div></div> <p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d19128dex991.htm">Press Release, dated June&#160;1, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</td></tr></table> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-2-</p></div></div> <p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:40%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">AMGEN INC.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: June&#160;1, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan P. Graham</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jonathan P. Graham</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, General Counsel and Secretary</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d19128dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g19128dsp1.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:18pt; font-family:ARIAL"><B><I>News Release</I></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">One Amgen Center Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">Thousand&nbsp;Oaks,&nbsp;CA&nbsp;91320-1799</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Telephone
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1000</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><FONT STYLE="font-size:10pt" COLOR="#0000ff"><U>www.Amgen.com</U></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>COMMERCIALIZE KHK4083, A PHASE <FONT STYLE="white-space:nowrap">3-READY,</FONT> POTENTIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FIRST-IN-CLASS</FONT></FONT> TREATMENT FOR ATOPIC DERMATITIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Agreement Renews Successful Global Collaboration That led to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Several Groundbreaking Therapies in Multiple Disease Areas </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>KHK4083 Depletes OX40-Expressing T cells Associated with Atopic </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Dermatitis and Several Other Inflammatory Diseases </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Moderate-to-Severe</FONT></FONT> Atopic Dermatitis Affects Nearly 30 Million People
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>in Major Global Markets<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Amgen to Host Investor Call at 8:00 a.m. ET </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">THOUSAND OAKS, Calif. and TOKYO, Japan, (June 1, 2021) -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to
jointly develop and commercialize KHK4083, which is Kyowa Kirin&#146;s potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> anti-OX40 fully
human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases. In February, Kyowa Kirin announced positive results from a Phase 2 study of KHK4083 in patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> atopic dermatitis, which affects nearly 30&nbsp;million people in major global markets<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Under terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for KHK4083 for all markets globally, except Japan,
where Kyowa Kirin will retain all rights. Additionally, Kyowa Kirin will <FONT STYLE="white-space:nowrap">co-promote</FONT> KHK4083 with Amgen in the U.S. and have <FONT STYLE="white-space:nowrap">opt-in</FONT> rights to <FONT
STYLE="white-space:nowrap">co-promote</FONT> KHK4083 in certain other markets outside the U.S., including in Europe and Asia. Amgen will make a $400&nbsp;million <FONT STYLE="white-space:nowrap">up-front</FONT> payment to Kyowa Kirin and future
contingent milestone payments potentially worth up to an additional $850&nbsp;million, as well as significant royalty payments on future global sales. Kyowa Kirin and Amgen will share global development costs, except in Japan, and U.S.
commercialization costs. Amgen will consolidate sales for KHK4083 in all markets globally, except for Japan. Amgen also will leverage unique data from its deCODE Genetics subsidiary to inform the potential use of KHK4083 in indications beyond atopic
dermatitis. The closing of the transaction is conditioned on obtaining any necessary consents and approvals. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL
FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;Kyowa Kirin has a long legacy of partnering with other companies to deliver the full value of our
scientific discoveries and novel medicines for patients,&#148; says Masashi Miyamoto, Ph.D., President and CEO of Kyowa Kirin. &#147;KHK4083 is an important asset in our global pipeline. We know Amgen well, and this alliance will build on the past
success and trust we have, bringing additional resources and therapeutic expertise to KHK4083&#146;s development and commercialization, to meet the needs of patients living with atopic dermatitis who seek alternative treatment options.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">KHK4083 is an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin and engineered with Kyowa Kirin&#146;s patented POTELLIGENT<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> defucosylation technology to enhance its antibody dependent cellular cytotoxicity (ADCC) activity. KHK4083 has been shown to selectively deplete activated T cells that are critical in the
development of atopic dermatitis. Kyowa Kirin antibodies powered by POTELLIGENT technology with ADCC activity are currently marketed in therapeutic areas including Oncology and Asthma. This potent antibody-enhancement platform is also licensed to
numerous third parties throughout the biopharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;Kyowa Kirin was one of Amgen&#146;s very first collaborators and we are
delighted to be joining forces with them once again to advance this promising late-stage asset to treat atopic dermatitis,&#148; said Robert A. Bradway, chairman and chief executive officer at Amgen. &#147;We will take advantage of our two decades
of experience in inflammatory disease, as well as our industry-leading human genetics capabilities, to help realize the full potential of KHK4083 as quickly as possible.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen is a global leader in treating inflammatory diseases, with a portfolio of marketed medicines that includes Otezla<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Enbrel<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, AMGEVITA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (a biosimilar to Humira<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), and AVSOLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (a biosimilar to Remicade<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Amgen&#146;s pipeline of
investigational therapies includes tezepelumab (filed for U.S. FDA approval in May 2021 as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> treatment for severe asthma), ABP 654 (a biosimilar
to STELARA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), and several innovative molecules in Phase 2b development for systemic lupus erythematosus and celiac disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;KHK4083 is another example of our world-leading expertise in antibody engineering, applied target selection and optimization. We are proud to be a
<FONT STYLE="white-space:nowrap">science-led</FONT> organization whose research capabilities continue to produce meaningful discoveries, while also taking advantage of open innovation, that offers potential for improving treatment paradigms,&#148;
said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of Global R&amp;D Division of Kyowa Kirin. &#147;Results from clinical trials for KHK4083, including Phase 2 data, show great promise and we look forward to initiating a late-stage
global program with Amgen to deepen our understanding of this asset.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">In 1984, Amgen and Kirin Holdings Co., Ltd (former Kirin Brewery Co.,
Ltd), the parent company of Kyowa Kirin, established a <FONT STYLE="white-space:nowrap">50-50</FONT> joint venture to develop and commercialize EPOGEN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (Japanese brand name: ESPO<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), which, in 1989, became the first Amgen medicine approved in the U.S., and, in 1990, became the first Kirin medicine approved in Japan. Over time, the joint venture expanded to include the
development and commercialization of several other medicines, including NEUPOGEN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (GRAN<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in Japan), Neulasta<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (G-Lasta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in Japan), Aranesp<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(NESP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in Japan), and Nplate<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (Romiplate<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in Japan). In 2017, the companies
announced that the joint venture would become a wholly owned subsidiary of Amgen, with Kyowa Kirin <FONT STYLE="white-space:nowrap">in-licensing</FONT> certain Amgen medicines in the Asia-Pacific region. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL
FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Amgen&nbsp;Webcast Investor Call </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen&nbsp;will host a webcast call for the investment community on&nbsp;June 1, 2021, at&nbsp;8:00 a.m. ET.&nbsp;Peter H. Griffith, executive vice
president and chief financial officer,&nbsp;David&nbsp;M. Reese, M.D., executive vice president of Research and Development, and&nbsp;Murdo Gordon, executive vice president of Global Commercial Operations at&nbsp;Amgen&nbsp;will participate.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and
the general public.&nbsp;The webcast, as with other selected presentations regarding developments in&nbsp;Amgen&#146;s business given at certain investor and medical conferences, can be accessed on&nbsp;Amgen&#146;s website, <FONT
STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0000ff"><U>www.amgen.com</U></FONT><FONT STYLE="font-family:ARIAL">, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on&nbsp;Amgen&#146;s
Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>About the
KHK4083 Phase 2 Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">In February 2021, Kyowa Kirin reported that KHK4083 met the primary endpoint in a Phase 2 randomized, double-blind and
placebo-controlled clinical study conducted in the U.S., Japan, Canada, and Germany. The study included 274 patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> atopic dermatitis, who were
not adequately controlled with topical agents. All KHK4083 cohorts achieved superiority to the placebo cohort for the primary endpoint of percent change from baseline in Eczema Area and Severity Index (EASI) at 16 weeks with statistical
significance. In addition, there was significant difference in the percentage of patients achieving an <FONT STYLE="white-space:nowrap">EASI-75</FONT> (EASI score of 75% or greater improvement from baseline) at 16 weeks and the percentage of
patients achieving the Investigator&#146;s Global Assessment (IGA) of 0 or 1 with an improvement of 2 points or more at 16 weeks in all KHK4083 cohorts compared to the placebo cohort. Further improvements in the efficacy of KHK4083 were observed
beyond week 16. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Common treatment-emergent adverse events for KHK4083 cohorts were pyrexia, nasopharyngitis, worsening of atopic dermatitis and
chills during the first 16 weeks. Pyrexia and chills events were mild to moderate in intensity, most of them were due to injection reaction and observed only after the first administration of the investigational product. There were no events of
severe hypersensitivity reactions and no deaths observed in the study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>About Atopic Dermatitis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Atopic dermatitis is a chronic disease in which the immune system becomes disordered and overactive, triggering inflammation that damages the skin
barrier. People with atopic dermatitis can get rashes anywhere on the body that can ooze, weep fluid and bleed when scratched, making skin vulnerable to infection. Skin can become dry and discolored, and repeated scratching can cause thickening and
hardening of the skin. Atopic dermatitis typically begins in childhood, affecting 15% to 20% of children and 1% to 3% of adults worldwide. The incidence of the disease has increased <FONT STYLE="white-space:nowrap">two-</FONT> to three-fold since
the 1970s. People who have asthma and/or hay fever or who have family members who do, are more likely to develop atopic dermatitis. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL
FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About OX40 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">OX40 is a <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> molecule that is one of the tumor necrosis factor receptor (TNFR) family members. It
plays an important role in maintaining T cell proliferation and survival and in the formation of memory T cells. OX40 is expressed on the surface of effector T cells (CD4 positive) activated by antigens. It has been reported that effector T cells
expressing OX40 are present in the lesions of atopic dermatitis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>About Kyowa Kirin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more
than <FONT STYLE="white-space:nowrap">70-year</FONT> heritage, the company applies cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas
including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions &#150; Japan, Asia Pacific, North America and EMEA/International &#150; we focus on our purpose, to make people smile, and are united by our shared values of
commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>About Amgen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen is committed to unlocking
the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the
complexities of disease and understand the fundamentals of human biology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen focuses on areas of high unmet medical need and leverages its
expertise to strive for solutions that improve health outcomes and dramatically improve people&#146;s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#146;s leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline of medicines with breakaway potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">For more information, visit www.amgen.com
and follow us on www.twitter.com/amgen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Amgen Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene,
Ltd. or any collaboration to manufacture therapeutic antibodies against <FONT STYLE="white-space:nowrap">COVID-19),</FONT> the performance of Otezla<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (apremilast) (including anticipated Otezla
sales growth and the timing of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS accretion), the Five Prime Therapeutics, Inc. acquisition, or the collaboration with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, as well as
estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement
activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Amgen&#146;s business, outcomes, progress, or effects relating to studies of Otezla as
a potential treatment for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and other such estimates and results.&nbsp;Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described
in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent periodic reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
and current reports on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or otherwise. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL
FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">No forward-looking statement can be guaranteed and actual results may differ materially from those
Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any
particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.
The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval
for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected.
Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as
effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the
market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen&#146;s results may be affected by its ability to successfully market both new and existing products domestically and internationally,
clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic
conditions. In addition, sales of Amgen&#146;s products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care
providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen&#146;s research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen&#146;s business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen&#146;s business
may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become
subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or
Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for
a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen&#146;s manufacturing activities,
the distribution of Amgen&#146;s products, the commercialization of Amgen&#146;s product candidates, and Amgen&#146;s clinical trial operations, and any such events may have a material adverse effect on Amgen&#146;s product development, product
sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen
competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen&#146;s products are supplied by sole
third-party suppliers. Certain of Amgen&#146;s distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen&#146;s products that
implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen&#146;s efforts to collaborate with or acquire other companies, products or technology,
and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability
of Amgen&#146;s systems and Amgen&#146;s data. Amgen&#146;s stock price may be volatile and may be affected by a number of events. Global economic conditions may magnify certain risks that affect Amgen&#146;s business. Amgen&#146;s business
performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are
favorable to it, or at all. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL
FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"> Page
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The scientific information discussed in this news release related to Amgen&#146;s product candidates is
preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific
information discussed in this news release relating to new indications for Amgen&#146;s products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are
not approved for the&nbsp;investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these&nbsp;uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">CONTACT:&nbsp;Amgen,&nbsp;Thousand Oaks, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Megan Fox, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1423</FONT></FONT> (Media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Michael Strapazon, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">805-313-5553</FONT></FONT> (Media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Arvind Sood,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1060</FONT></FONT> (Investors) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">CONTACT: Kyowa Kirin, Tokyo, Japan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Hiroki Nakamura (Global, Japan), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+81-3-5205-7205</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Lauren Walrath (North America), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+01-646-526-4454</FONT></FONT></FONT>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Stacey Minton (EMEA), +44 (0) 7769 656073 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Joice Toh (Asia/Pacific), +65 8725
2790 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL
FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"> Page
 7
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B><U>References </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:ARIAL; " ALIGN="justify">Decision Resources Group, Atopic Dermatitis/Atopic Eczema Disease Landscape&nbsp;&amp; Forecast, April 2021. <SUP
STYLE="font-size:85%; vertical-align:top">&copy;</SUP> [2021] DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission. Major global markets are the U.S.,
France, Germany, Italy, Spain, the U.K. and Japan. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20210601.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.3 -->
<!-- Creation date: 5/30/2021 2:18:52 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:amgn="http://www.amgen.com/20210601"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amgen.com/20210601"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20210601_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20210601_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20210601_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amgn_A1.250SeniorNotesDue2022Member" name="A1.250SeniorNotesDue2022Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_A2.00SeniorNotesDue2026Member" name="A2.00SeniorNotesDue2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20210601_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.3 -->
<!-- Creation date: 5/30/2021 2:18:52 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20210601.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="amgn-20210601.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:loc xlink:href="amgn-20210601.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntitiesTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A1.250SeniorNotesDue2022Member" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CityAreaCode" order="30.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="32.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="33.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="34.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="35.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_Security12bTitle" order="38.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_TradingSymbol" order="39.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="40.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="41.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="43.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="44.001" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20210601_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.3 -->
<!-- Creation date: 5/30/2021 2:18:52 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="amgn-20210601.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A1.250SeniorNotesDue2022Member" xlink:to="amgn_A1.250SeniorNotesDue2022Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A1.250SeniorNotesDue2022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">1.250% Senior Notes Due 2022 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A1.250SeniorNotesDue2022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.250% Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:href="amgn-20210601.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A2.00SeniorNotesDue2026Member" xlink:to="amgn_A2.00SeniorNotesDue2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.00% Senior Notes Due 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20210601_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.3 -->
<!-- Creation date: 5/30/2021 2:18:52 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20210601.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitiesTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_EntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20210601.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A1.250SeniorNotesDue2022Member" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20210601.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CityAreaCode" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_Security12bTitle" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_TradingSymbol" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g19128dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g19128dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( #H S0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * $SB@ S1L M !0 4 % !0 4 (3B@ S0 9H 6@
M H * "@ H * "@ H .E "9H -U KBT#"@!"<4 8&N^,=(\/Y2ZFWW&.(8OF;
M\?3\:Z*6&JU=8K0Y*^,I4=&]3BKGXN2[S]ETI0G_ $TE.?T%>C'+.\CRY9L[
MZ1-0?$&X3PFFM/81EFN3 8PY QC.<UB\"O;>SOTN="S!^P]JUU+>A_$O2=3E
M6"Z1K&9N!YARA_X%V_&LZV JT]5J:4,RI5=):':*P901TK@V/23N.H&0W%U#
M:0//<2+%$@RSL< "FDV[(ER45=['!:K\5=/MI6CT^TDN\?\ +1CL7\.]>E3R
MZI)7EH>35S6G%V@KG8Z/J?\ :.B6NH2HL7G1B0C/"_C7!4AR3<%T/2HU.>FI
MOJ<?X@^)]G8RM;Z7"+N5>#(QQ&#[>M=]#+YS7-/0\[$9G"#Y:>IQT_Q)\2RO
MN2ZBA']U(EQ^N:[XY?06Z/,EF>(>S+-A\3]<MI!]J$-W'W#)M/X$?X5$\NIO
MX=#2GFE5/WM3T?PYXPTWQ$FR!C%= 9:"3[WU'J*\JOA9T'KL>SA\93KK3<L>
M)O$2>&M+6^DMVG4R"/:K;>H//Z5&'H^WERIV-,3B%AX\S1R'_"WK7_H$3?\
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M7Q%\-[>[.%G6Z1)E'9@K?H>M>/AJ/L,5ROL>WBJZQ&$NM[GFZJS,%52S$X
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MQ-Y'^V.#_0UP9=5<X.+Z'HYE14)J2V9QFX[0N3@=!Z5Z*2/,N[6.X\-:0J>
M]>U:1?WDD1BC/HHQG]?Y5YF(JWQ,(+H>MA:*^K3FSANE>H>0% SVOX7W4<OA
M)85(WP2LK#ZG(_G7SN81:K7/J,KDG0MV&_%&&6?PO$L,;2-]H4X523T-& :C
M5U#,DY4M#Q_^S[W_ )\Y_P#OV?\ "O>]K#NCYKV53^5D$D;Q.4D1D8=0PP:M
M-/5$-..C&TQ"@$D #)]*0%C^S[W_ )\Y_P#OV?\ "H]I#NC3V4_Y6=2T,L'P
MLD66-XV_M '#*0?NUQ*2>+33Z'H.+C@K-=3C:]'L>6:NN:'<:)- LOS0W$2R
MQ28X8$=/J*YZ%=5D[;IG3B*#HM>:,JN@YCOOA/\ \C'=_P#7N?\ T(5Y>9?P
MH^I[&4_Q7Z'L5>"?2!0!5O[N.PL)[N4XCA0NWT S3A#FDHF=2?)!R['S?>74
ME[>3W4QS+,Y=OJ3FOKJ<5""CV/BZDW.;EW.JT3X=ZCK>DPZA'=00QS9*JX.<
M X]*X*V/C2FX6/0HY;.K!33+[?"?5$1F-_:\#/1O\*S69QO\)J\IFE=LX%EV
ML5SG!Q7JIW5SR&K-HZM_^26Q?]A$_P#H-<7_ #&?([_^8+YG,6W_ !]0_P"^
M/YUUS^%G##XD>L_%:V$GA^SN<<Q3[?P8'_ 5X>6RM5<?(^AS6%Z*D>0U[Y\V
M>Q1VPM/@\R 8+69D/_ N?ZU\]S<V,OYGTRAR8'Y'CM?0'S)KZSH[Z?;Z==A3
MY-Y;K(IQQNQ\P_K^-<]&MSRE'JF=5>@Z<8RZ-$OA?Q-<>&=1\^-?,@D^66+.
M-P]O>IQ&'5>.NY6$Q4L-._0]=T_QWX>OH0_]H1V[8Y2?Y"/SXKPIX.M!V2N?
M1T\=0FKWL9^N_$C2+"W==/<7MSCY0GW ?4G_  K2C@:DW[VB,:V8TJ:M'5GC
MM[>SZA>RW=S(7FE;<S>IKZ&G3C3BHH^:J3=23E+<TTT9T\(S:O*N ]PD,6>X
MPQ8_H/R-<[K7KJFNAO[%^Q=67<RK6407<,K E4=6('L<UT33E%I=3G@^62?8
M]<'Q7T;'_'I=_P#?*_XUX?\ 9M7NCZ+^U:2TLRAXQ\06WB/P&;RUCD1%NU3$
M@&<@'T^M:86C*CB.678QQM>.(PO-'N>6U[;T/!/;?$&A+KG@*W55S<V]LDL1
M[Y"C(_$5\Y0KNCB&_,^HQ%#VV&26Z1XE7T>G0^79WWPG_P"1CN_^O<_^A"O+
MS+^%'U/7RG^*_0]BKP3Z0* .-^(]Q/'X7:VMHY)'N9 A"*3A1R>GT _&NS!*
M+JW;/.S&4E1:BMSQU-*U!W"BQN,MP/W3?X5]#*M35VI'S<:,VTK/[CZ'TFR3
M3M(M+- ,01*GY"OE:DG*3;/L*,.2"B6)Q^Y<#^Z:E;HN7PL^<)--O_-?_0KC
MJ?\ EDW^%?5QJT[+5'QDZ-2_PLZ@V%XWPSCA6TG,HU ML$9SC;UQ7&IQ6*O=
M6MW.[V<WA+6=[]CG+?2-2%S$3I]R!O'_ "R;U^E=<ZL.5ZK[SBA1J*2]UGK_
M ,0[:6Z\'2I#$\D@DC(55R>M>#@I*%=-GT>/@Y8>RW/'/['U/_H'77_?IO\
M"OH/;0[K[SYKV%3^5_<>T:G;2+\-7MEB8RBQ50BC)SM'&*^=IR_VB[[GU%2+
M^JV\CQ<:/J?_ $#[G_OTW^%?1>VI7W7WGR_L:FW*_N/8[/P]#K?@"PT^]C:-
MQ I4D8:-AWKYZ5>5&O*<>Y]+##QK8:,)=CRK7O"NI^'IV6Y@9X,_+.@RC#^G
MXU[E#%0JK>S/ KX2I1=GL8G/:NJYR>H8YP!S2NEN"5]CL/#'@#4-9F2:]1[6
MQZEG&&?V4?UKS\3C84](:L]+"X"I5?-+1':?$+3?*\&6]E86K%(IT"QQ*3@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d19128d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20210601"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20210601.xsd" xlink:type="simple"/>
    <context id="duration_2021-06-01_to_2021-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-06-01_to_2021-06-01"
      id="Hidden_dei_EntityCentralIndexKey_duration_2021-06-01_to_2021-06-01">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="duration_2021-06-01_to_2021-06-01"
      id="Hidden_dei_AmendmentFlag_duration_2021-06-01_to_2021-06-01">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="duration_2021-06-01_to_2021-06-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-06-01_to_2021-06-01">2021-06-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-06-01_to_2021-06-01">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-06-01_to_2021-06-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-06-01_to_2021-06-01">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-06-01_to_2021-06-01">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-06-01_to_2021-06-01">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-06-01_to_2021-06-01">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-06-01_to_2021-06-01">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-06-01_to_2021-06-01">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-06-01_to_2021-06-01">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-06-01_to_2021-06-01">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-06-01_to_2021-06-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-06-01_to_2021-06-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-06-01_to_2021-06-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-06-01_to_2021-06-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">1.250% Senior Notes Due 2022</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">AMGN22</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-06-01_to_2021-06-01_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-06-01_to_2021-06-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140578627075816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member', window );">1.250% Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes Due 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">2.00% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.000% Senior Notes Due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( ! QP5*FXQCK[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( ! QP5*97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ $#'!
M4H)5AGW5!   0!8  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( ! QP5*?H!OPL0(  .(,   -
M      "  1@-  !X;"]S='EL97,N>&UL4$L! A0#%     @ $#'!4I>*NQS
M    $P(   L              ( !] \  %]R96QS+RYR96QS4$L! A0#%
M  @ $#'!4APX9>H_ 0  / (   \              ( !W1   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ! QP5(D'INBK0   /@!   :
M  "  4D2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ! QP5)ED'F2&0$  ,\#   3              "  2X3  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  '@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d19128d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d19128d8k.htm">d19128d8k.htm</File>
    <File>amgn-20210601.xsd</File>
    <File>amgn-20210601_def.xml</File>
    <File>amgn-20210601_lab.xml</File>
    <File>amgn-20210601_pre.xml</File>
    <File>d19128dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d19128d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 4,
   "dts": {
    "definitionLink": {
     "local": [
      "amgn-20210601_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d19128d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20210601_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20210601_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20210601.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 2,
   "memberStandard": 1,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20210601",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d19128d8k.htm",
      "contextRef": "duration_2021-06-01_to_2021-06-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d19128d8k.htm",
      "contextRef": "duration_2021-06-01_to_2021-06-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 3,
   "tag": {
    "amgn_A1.250SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.250% Senior Notes Due 2022 [Member]",
        "terseLabel": "1.250% Senior Notes Due 2022 [Member]"
       }
      }
     },
     "localname": "A1.250SeniorNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20210601",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "terseLabel": "2.00% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20210601",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amgen.com//20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-177693-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-177693-xbrl.zip
M4$L#!!0    ( ! QP5*/3_9[S0,  ,@.   1    86UG;BTR,#(Q,#8P,2YX
M<V3-5UUOVS84?2_0_\#I:0,F47+@;!'B%,'<# :2K'#286\!+5T[Q"A2(ZG$
M_O>]I"1;_JS=%-OR$HH\Y_)<W@_2EQ_FA2 OH U7<A D41P0D)G*N9P-@LJ$
MS&2<!Q^NWK^[_"$,R?!F=$]"\FQM:5)*7U]?HWS*I5&BLFC!1)DJ* G#%O_;
MXV?R9VT])>>_1&?=-0W,D4C.+*2D3\]BVHM[">FER:]IOT<^W9&/S%C0DCSR
M KI452XTGSU;\F/V$_&DH9(2A( %N>&2R8PS01Y:63^3D<PB<BT$&3N:(6,P
MH%\@CQJK<Y.G)GN&@KU_1P@>BC0I*V9X)L[7QE6< .E==%O&YW$2K-#SB19\
M#>YF(J5GB([/*)Z215W0H0@N_S[ <,L39KJ,^1;E]<P3DHN+"^I7-R3E=@GO
M6N_3>K&#EGB"5;%;3VXUM8L2*()"1('F69?Z==X6!Y-KQEBYY$V9F7A.L^#.
M. [C)#SKGG(.?-T? UDT4R\4%W8ST)Q38'9NY%<V><Q:S2>5A1NEBR%,627P
M$"OY3\4$GW+(/0H$%"#M&F8=89F>@;UG!9B297!"*IE\5XPQ; G]Z^[VP>=I
M<.4(A/C4Y46IM"5U!M^JS!?6@=1R7V&;D:&;"I,>^A^AL8#(G9+WI#.A;Q;2
M)OHW"5E6R5N$M.7@%/3W[;VS?KYYU\W2<%M?..>3\Z.<WRJM[Z!$R?NWBNGT
MAZ,%F7W%[ ;AJCH/!F9/(SCE5+R=G7V(@K"FG3E"T:%F]IT5^19VHJ2MMM=H
M\HJ8E,IZ&5V=K"RYG*IF"B==W:5M\8UA2OSMDS*=:27@\!U%2ZU*T):CBE7]
MU@:>-4P'@;M[P[8U/@DVB; UMI"M#=8[@ENF2 %QNY+7<BVWCGSKEHE;Q\<!
M$TO3[F0&@<&HB$Y'^9?=+36<ZBY2#-Y&/FS[O?[40?U?G<]A>JKS2.&2'W9]
MN,2<[+C;XQ$1Q T^CT=[+O+E34XMFRNIBD6M;JBRRKT4VO_7,O\H4=5BA/6D
M"Q^,@'"\\L<(?SH*OE38:EP=P542NS]\I;<6ND,F<U*;(QU[EW33R*;]RD#^
MA[SRXXR)K!++5&O(#>(0<3-)CV>N1W@WKYEMH]4V+[K9O9J9]2[G>USSI/.Q
M<$GY=)U$O7[\ )(K?:\LF&$%&.7>'103T'67'01?0]7953^OTUP5C,N1A<*)
M#(BI)@;#X7^G_*Y5A0]B_TLBY0C!_/1CK!^N\D=O)Z]TDS*2"^QR+KFMKM 4
M0TN:9;;]IH<\ZT7QMN3S#<<.@_Y+O^H@UK<F?GX!4$L#!!0    ( ! QP5(L
M^"AJTP4  $0U   5    86UG;BTR,#(Q,#8P,5]D968N>&ULW5M;;]LV&'T?
ML/_ J2\;,%W=I(U1KS!R*8SEAMC=AKT$M$3;1"G2(*G$_O<C93&1+=F1LK%K
M]>(+S>_P'(KZ/NH0_O!QE1+P@+C C Z<T L<@&C,$DSG R<3+A0QQL['WW[\
MX<-/K@O.+D;7P 4+*9>B[_N/CX]>,L-4,)))A2"\F*4^<%W3_W3R&?RQ0>^#
MXW=>K_P;1U '@01*U ='?B_PHR *0=0/W_>/(G![!<ZAD(A3,,$I*H>RY9KC
M^4*"G^-?0!YTQBA%A* UN, 4TAA# L:&UJ]@1&,/# D!=SI,@#LD$'] B5>@
M$DR_]/7+% H$U*10D7\=.%IK(74UY<1C?*YH!CW?]':*[BN!MWH_]DS?T/_K
MZG(<+U *73594M%[CJJ,4L2%)R<G?O[K4U<U?"*?^I;9'/F;'U57@?LB'^J2
MQ?G\-I  ]O;0WUS3S=5-;ABYO=!;B<11$P? 9NH@CSDCZ [-0,ZY+]=+-' $
M3I=$:\W;%AS-]K(Q$O0@1QK^#23$ 07PY[M153BFTD]PZA=]_#S M\Q*#8BH
M7M!N@F8P([(=QYKPK\B8I1#35Q,NHJWSS<=Q4Y1.$6])=CO4-M.%@N!Q-D7N
MTRRUXUL+4&9M*.\B:FXPG2.:9]P\;P;'*M%(N&*4I6L_AS]C<:9@I7D?TN2<
M2BS7(SIC/,W3P[9TA4E=@Y9KO%- ]VV MN>U+$:M>$RQ[GNIOFYU1RN):((2
M Z+IVQ";LS%\"(LKUUV8RR50[,W9@Y\@K$<,] <],X$;A$4"?*.:[O,Q,!(3
M.'U>1QM11&=@QDTC@5-$!DY-D&^)5EFZFG(TDB@5K3CN07B9L.$[@V*:+WVU
MF9A#N-R01D0*T[++OFB^'TNU+] 7\I1 (6YF8\GB+\,5;B2@ <C7T% >]:Q(
MG\W)UT5_CZSOHZ_$FZ4IH_G 5T4%:$&[&GR8<S55ZI;[8>A%1\$84<SX-9-(
MG&5(]8J:,VH$\SIND1=4,8_;4CN,8B&9F90^4=2:IJ_M&(ND;A''3)6:Y$RE
MFK;L=H*M%8([-,="<DCE-4S;E:E*K,5J%3.^9#RO-GGF/F49E7Q]RI*6G%^
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M8'!_?]^?SKB(,5PD2C+N!Q@-P/.*^./KS_!75NX ]G_M[Y6W2>;K))CZ"3N
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M:)5/YI_H5EO,+_,O8;KE7U!+ P04    "  0,<%2(NVV%.(4  !YB   #0
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MPF<AZO3#^EH[HK]W#/^]IT[ "RI!/'T*OO(;TOMFIE7S#:_:J>,'K-)]W35
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M>;DF,9TKSC"0_?#I99N))2*CI3->[AA1A^2:1T8A20(6$Z-@M'C):.(S>D.
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M^>;'[G$UR(-)ZF<0OO2O#[:^MGE*TOI]J,%2GR+2?0"V4YL79%(?.DA%%->
MGV[OO!3YK;*,ZVMU"9C]V+)TW]@R#J$S=H;R$WE9Y(+L#6H C6J$CWP[2SF>
MN\T6V67) Y"P>^OERV=M_<Z]7J,ZUCW7 6<_:<8,+!8QU&+G[S<U&?\H5/PH
M5'Q+H>+9OWNAHFI6DI?\:D:!7NI8NJ-#Z<5WSG((*9POFJ)]BNR+(RL -;X;
M1H)95\U%=POREM8]W6Q@(N-;R*?-OJN>?'1NT-G^J:<^9A&!Z6+:::2SKLD
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MZMV=IX\GQUY/QPU>$2P,=,(3YA(8U^%7O(!(S\G/=A:[6.ZQ#^J6O0%ZU=Z
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M8.;8$L(^LMX6).9?FCIM7$H20J"(I+/(NI+UGF)KK\31O&29AL>4",_?*#;
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MVC[ ?J3N F/.\G%=$D$WPA%OIVY=)FE,"-& 'XU*O[(K_7'5 [1\%,6J^QO
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M,#(Q,#8P,5]D968N>&UL4$L! A0#%     @ $#'!4D-!U KB!P  SU@  !4
M             ( ! @H  &%M9VXM,C R,3 V,#%?;&%B+GAM;%!+ 0(4 Q0
M   ( ! QP5(H[(X4@04  ' X   5              "  1<2  !A;6=N+3(P
M,C$P-C Q7W!R92YX;6Q02P$"% ,4    "  0,<%2(NVV%.(4  !YB   #0
M            @ '+%P  9#$Y,3(X9#AK+FAT;5!+ 0(4 Q0    ( ! QP5*<
MRQF?C28  &Z)   0              "  =@L  !D,3DQ,CAD97@Y.3$N:'1M
64$L%!@     &  8 @0$  )-3      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
